Aquestive Therapeutics, Inc.
NASDAQAQST short sellers face mounting borrow costs: utilization hits 92.37%, near 52-week peak of 96.51%, while availability rebounds to 25% after dropping to 6% last week.
Snapshot as of 14 Aug 2026
Aquestive Therapeutics heads into today's earnings print with options traders at their most defensive in a year, even as short sellers show early signs of pulling back. The options market is sending the loudest…
Aquestive Therapeutics enters the final week of June carrying two contradictory signals: the stock is up 7.6% over the past month — riding a 43.77% spike after the FDA waived an advisory committee meeting for its…
Aquestive Therapeutics reports Q1 results today with a notable insider selling cluster dominating the pre-earnings backdrop. The insider signal is the sharpest data point heading in. Five executives — including the…
Aquestive Therapeutics heads into its Q1 earnings release tomorrow with the entire C-suite having sold shares within the past week — a cluster of insider exits that frames everything else on the tape. The insider…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AQST — free to start on ORTEX.
Sign up for free →Open AQST on ORTEX